Quantum mechanics approaches to drug research in the era of structural chemogenomics

Authors

  • Andrey V. Ilatovskiy,

    1. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093
    2. Division of Molecular and Radiation Biophysics, Konstantinov Petersburg Nuclear Physics Institute, NRC Kurchatov Institute, Gatchina 188300, Russia
    Search for more papers by this author
  • Ruben Abagyan,

    1. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093
    Search for more papers by this author
  • Irina Kufareva

    Corresponding author
    1. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093
    • Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093
    Search for more papers by this author

Abstract

The rapid growth of the available crystallographic information about proteins and binding pockets creates remarkable opportunities for enriching the drug research pipelines with computational prediction of novel protein–ligand interactions. While ab initio quantum mechanical (QM) approaches are known to provide unprecedented accuracy in structure-based binding energy calculations, they are limited to only small systems of dozens of atoms. In the structural chemogenomics era, it is critical that new approaches are developed that enable application of QM methodologies to noncovalent interactions in systems as large as protein–ligand complexes and conformational ensembles. This perspective highlights recent advances towards bridging the gap between high-accuracy and high-volume computations in drug research. © 2013 Wiley Periodicals, Inc.

Ancillary